Drug profile

The FDA adverse-event record for Atropine Sulfate

34 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Atropine Sulfate. See the species affected, top reactions, and outcomes below.

34
adverse-event reports
26.5%
death-coded share
Dog
most-reported species
6
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
34
Total Reports
9
Deaths Reported
26.5%
Death Rate

Active Ingredients

Atropine Sulfate

Administration Routes

UnknownOphthalmicOralOtherIntramuscularSubcutaneous

Species Affected

Dog 29
Cat 4
Horse 1

Most Affected Breeds

Unknown 5
Chihuahua 3
Shar Pei 2
Retriever - Labrador 2
Shepherd (unspecified) 2
Collie - Border 2
Terrier - Yorkshire 1
Pug 1
Domestic Longhair 1
Dachshund - Standard Long-haired 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 6
Hypersalivation 6
Eye disorder NOS (for photophobia see 'neurological') 5
Vomiting 5
Death 5
Other abnormal test result NOS 4
Diarrhoea 4
Thrombocytopenia 3
Emesis 3
Pale mucous membrane 3
Death by euthanasia 3
Abnormal ultrasound finding 3

Outcome Breakdown

Recovered/Normal
16 (47.1%)
Died
6 (17.6%)
Ongoing
5 (14.7%)
Outcome Unknown
4 (11.8%)
Euthanized
3 (8.8%)

Atropine Sulfate Adverse Event Insights

34 reports name Atropine Sulfate; 9 recorded a death outcome (26.5% of reported events, not a population-level mortality rate). Active ingredient: Atropine Sulfate. Administration routes: Unknown, Ophthalmic, Oral, Other.

By species: Dog (29 reports), Cat (4 reports), Horse (1 reports). By breed: Unknown (5), Chihuahua (3), Shar Pei (2).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (6), Hypersalivation (6), Eye disorder NOS (for photophobia see 'neurological') (5), Vomiting (5). Outcome, 34 coded reports: Recovered/Normal leads at 47.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.